|Número de publicación||US5330756 A|
|Tipo de publicación||Concesión|
|Número de solicitud||US 07/980,839|
|Fecha de publicación||19 Jul 1994|
|Fecha de presentación||24 Nov 1992|
|Fecha de prioridad||18 Oct 1990|
|También publicado como||WO1992006701A1|
|Número de publicación||07980839, 980839, US 5330756 A, US 5330756A, US-A-5330756, US5330756 A, US5330756A|
|Inventores||Gary M. Steuart, M. Conrad Huffstutler, Jr.|
|Cesionario original||Steuart Gary M, Huffstutler Jr M Conrad|
|Exportar cita||BiBTeX, EndNote, RefMan|
|Citas de patentes (1), Otras citas (4), Citada por (51), Clasificaciones (60), Eventos legales (5)|
|Enlaces externos: USPTO, Cesión de USPTO, Espacenet|
This invention relates to medicaments containing Concentrated fluid (CF) Extracts of Plant species taxonomically identified as Symphytum, Aloe or Taxus, processes for their preparation in various forms and methods for use of the several medicaments and fore for therapy on humans and other mammals.
A. CF Symphytum Extracts
Alcohol or glycol extract solutions of plants reported to be S. officinale, which is called "comfrey" in English, are well known as wound-healing agents as used in topical preparations. Typically, dried "comfrey" roots/leaves are extracted at room temperature in solvents such as ethanol and the resulting solution will contain at least trace amounts of some of the known medicinal agents including allantoin, asparagine, and mucoplysaccharides. As with all medicinal or herbal plants, the actual chemical constituents of in-vivo plant parts are highly dependent upon the maturity at harvest, available soil moisture and nutients, and environmental factors such as pollution, climate parameters such as growth-season degree days and freedom from disease and insect infestation. Classic herbal medicine references do not have any definite values for the actual level of identified active components in the resulting extracts, or indications as to the probability of dangerous impurities and contaminants which may also be present. This continuing lack of specificity concerning how to grow and harvest selected plant types, what plant parts to extract, how to do the extraction to get optimal or efficient therapeutic concentration is no doubt responsible for the various "comfrey" controversies such as poisoning of humans and animals due to pyrrolizidine alkloids. For products marketed in USA, the FDA has determined that no therapeutic claims can be made for any old-type "comfrey" compositions which have not been subjected to comprehensive lab/animal/and clinical validations according to detailed IND and NDA procedures.
It has long been desired to develop topical compounds with concentrated levels of healing extract that are high enough to give a distinct healing response to skin or mucous membranes while at the same time having skin moisturizing properties. The "ideal" product should have an extended shelf life e.g., 9 months to 2 years. Further, it is desirable that the product does not create skin irritation i.e., a burning sensation on an open wound such as occurs with alcohol or propylene glycol preparations containing "comfrey".
"Comfrey" has been recognized for decades for its healing properties, particularly for its ability to stimulate epithelial development externally in the case of skin damage or breakdown and internally in the case of stomach ulcers. Original applications were using a "comfrey" tea made by boiling the leaves and stems or the roots in liquid water for a short time. The filtered liquid-solution product, tea, was taken orally for various medical symptoms or it could be applied externally to the skin surface. MacAllister (1902) reports that poultices were made by mashing or grinding fresh "comfrey" leaves or roots and applying the resulting fibrous slurry directly to wounds to stimulate healing. Alcohol tinctures were made by using pure liquid alcohol as defined by the U.S. Pharmacopeia and water to extract the healing properties from "comfrey" roots. After filtration to remove the solids, that tincture was used for external applications to promote healing. Homeopathic Pharmacopeia (1978) describes a typical preparation method based upon dissolved "comfrey" extracts. No patent or research publication could be found which describes extraction of "comfrey" by fluids other than single-phase, single-component liquids.
U.S. Pat. No. 3,930,000 teaches that solvent extracts of the roots of plants reported to be "comfrey" contain a natural predecessor of synthetic allantoin which is known as 5-ureidohydantoin in the chemical literature. U.S. Pat. No. 4,670,263 discloses ointments containing stem and leaf extracts, using filtered propylene glycol, of "comfrey", along with additives including synthetic allantoin, ascorbic acid, chlorophyll, carotene and lanolin which are claimed to be effective for treating bovine mastitis and bovine metritis. The teaching states that either "green" or "dried" plant parts may be extracted with aqueous propylene glycol solutions to produce "comfrey ointments" based upon mixing "comfrey extracts in propylene glycol" with oily ointment-bases such as mineral oil and lanolin. The specification is silent on the question of micronutrients/trace minerals which must be present in the soil and any preferred horticultural procedures (average daytime sunlight intensity, growth-season degree days, average soil temperature, timing of harvest in growth season, soil and air moisture, soil nutrients, etc.). The specification does not teach any method of selecting plants according to maturity, health/freedom from plant diseases, or contamination/freedom from residues of agricultural chemicals such as herbicides, pesticides. Curiously, the specification does not mention the known carcinogenicity/hepatotoxicity of pyrrolzidine alkaloids derived from "comfrey". Neither does the specification mention the known tendancy of PG (propylene glycol) topical-pharmaceutical vehicles to produce skin sensitization, eczema, skin irritations and allergies when present in concentrations exceeding the isotonic concentration of 2%.
These "comfrey propylene glycol extracts" appear to be defined by the process of soaking from 283-681 grams of "green comfrey plant" in about 3931 grams of liquid propylene glycol (PG); after "filtration" to remove suspended solid matter and the coarse fibrous material, the filtrate solution is then further diluted with about 421-3459 grams of water. The teaching indicates that the PG solution may be heated to 99 deg. C. to "increase the rate of extraction"; however, no specific extraction time is given. Because no data are given for the weight of solids separated by the "filtration" step of the technique, it is impossible to calculate the actual resulting level of "comfrey extract" dissolved and/or dispersed in either the propylene-glycol stage or the final-dilution stage. By analogy with other extracts from plant tissue, it is estimated that the active "comfrey components" extracted by typical practice amounts to approximately 0.01 to 0.02 wt. % of the final diluted preparation. U.S. Pat. No. 4,847,084 discloses two ointments for treatment of decubitus ulcers, Decubitane #1 and #2, which are based upon a debriding enzyme, fibrinolysin, with additives including chlorophyll and povidoneiodine. U.S. Pat. No. 3,622,668 discloses a scar-inhibiting lotion for treatment of livestock injuries which contains phenol, retinol, ergosterol and olive oil, or fish oil. None of the disclosed or claimed "comfrey" treatment formulations for humans or other mammals are foams, controlled-release particles, controlled-release implants, emulsions, vesicles, liposomes, aerosols or micelles.
Several commercial sources offer "comfrey-containing" topical ointments e.g., human or veterinary grades, for treatment of skin irritations, rashes and minor wounds. These consist of "comfrey" liquid ethanol extracts mixed with an oily base. These oily bases typically contain various oils including almond and other vegetable oils blended with beeswax. Any suspensions or slurries present in these products appear to be stable against separation upon shelf storage at room temperature at least for a short time.
Commercial products that are labeled as containing "comfrey" extract appear to have variable "comfrey" contents below 0.01 wt. %. Generally, commercial "comfrey"-containing products are comprised of formulas with the base having over 50 wt. % wax and oil, high levels of propylene glycol, and/or high levels of alcohol. No evidence can be found of a true O/W emulsion with either consistent or high levels of "non-water comfrey components" in the final formulation i.e., greater than 0.02 wt. %.
In order to evaluate the characteristics of propylene-glycol-based "comfrey" extracts with 25-75 vol. % propylene glycol, experimental solution-type topical formulations were prepared and applied to various kinds of human skin injuries and diseases. Although these extracts exhibited healing properties on epithelial tissue, their use often produced an undesirable skin irritation and burning sensation on an open wound or sensitive skin areas.
One outgrowth of the experimentation was the development of a preparation which consisted of a dispersion of an aqueous phase into an oil-based phase, i.e., a W/O or water-in-oil emulsion. The dispersed, water-solution phase consisted of 75 vol. % propylene glycol, balance water and "comfrey" extracts. The continuous oil phase was made of mineral oil and lanolin. "Comfrey" components made up 0.004-0.01 wt. % of the resulting formulation. This emulsion proved to be unstable upon shelf storage at room temperature.
After extensive experimentation with processing variables, a stable W/O emulsion was prepared that contained about 0.01 wt. % Symphytum components in the dispersed propylene glycol solution phase and a blend of beeswax, lanolin, and vegetable oil in the continuous oil phase.
B. CF Taxus Extracts
Taxines, baccatins, and taxol are the principal medicinal constituents which can be extracted from components of species identified taxonomically as T. baccata, T. brevifolia, T. canadensis, T. chinesis, T. cuspidata, T. floridana and other wild or non-wild types. Extractable plant elements include flowers, seeds, needles, leaves, buds, nuts, cones, blooms, branches, stems, bark and roots. The alkaloids in extracts are poisonous to humans and animals if taken internally; typical symptoms include GI irritation, and failure of circulatory and respiratory functions. Experimental parenteral "taxol" preparations (developed by chemical modification and synthesis) are believed to be useful, along with other known radiation and chemotherapy technics, for treatment of certain tumors. Bitter disputes between EPA and several environmental groups have essentially halted scientific progress in this field in USA.
No publications on: (a) poly-phase, fluid-extraction processes or Co) fine-disperse mammalian therapeutic forms can be found for extracts of plant parts of any Taxus-type plant.
C. CF Aloe Extracts
Aloin, is the principal medicinal constituent of thickened, leaf-cell fluid of species identified taxonomically as A. perryi, or A. vera and other wild or non-wild types; the other constituents include resin, emodin and a mixture of volatile oils. Extractable plant components include flowers, seeds, leaves, anthers, buds, blooms, stems and roots. Aloin isolates administered orally are known for cathartic and purgative use. According to the lore of herbal medicine, "aloe extacts" are useful for skin care and moisturization.
No publications on: (a) poly-phase, fluid-extraction processes or (b) fine-disperse mammalian therapeutic forms can be found for extracts of plant parts of any Aloe-type plant.
The main object of this invention is the preparation of Concentrated Fluid Symphytum Extracts (CFSE) are prepared for therapeutic use by means of single or polyphase extraction in a dosed, controlled environment from comminuted Symphytum plant matter. Single phase extraction means that a fluid in liquid or gas phase will be in contact with the plant parts to be extracted. Polyphase extraction means more than one phase of an extract fluid will be present in the environment, either simultaneously or chronologically, i.e., sequentially by the condensation of a vapor phase to produce a liquid phase. For the purpose of this specification and claims, CFSE are defined as those organic and inorganic constituents which are: (a) present in either fresh or air-dried plant matter, including at least one of the plant elements comprising flowers, seeds, leaves, anthers, buds, blooms, stems and roots, of any one or more wild or non-wild Symphytum species including S. officinale, S. asperum, S. armeniacum, S. tauricum, S. sylvaticum, S. peregrinum, S. anatolicum, S. icaricum, S. orientale, S. kurdicum, S. pseudobulbosum, S. uplandicum, S. circinale, S. ottomanum, S. icaricum, S. brachycalyx, S. aintabicum, S. longisetum, S. bornmuelleri, S. tuberosum, S. bulbosum, S. ibericum, or S. longipetiolatum, harvested at a mature stage i.e., peri-bloom, and (b) can be extracted in a controlled or recirculated environment with fluids in either a liquid or vapor state from whole parts or comminuted particles of any or all of the above-named plant elements at temperatures in the range of 15-110 deg. C. with an extractant-fluid contact interval of 1 to 200 hours and with starting input weight ratios of extract fluid/plant matter of 0.01/1 up to 10000/1. According to this definition, the fluid may be initially a vapor phase which permeates into the plant elements and will under equilibrium conditions and then nucleate and condense a liquid phase on and within the plant elements. Further, according to this invention the fluid may initially contain medical-type surfactants which enhance its capillary flow within the structure of the plant matter. Further according to this definition, the types of defined contact between the plant elements and the extracting fluid include gravity flow of a liquid condensate, gravity drainage of a liquid fluid sprayed from the upper zones of the reactor, circulation/fluidization by means of vapor phase with or without a dispersed equilibrium aerosol and forced convection circulation/fluidization by means of a liquid fluid. For such flow variations, the forced-convection-contact-velocity differential would fall in the range 0.01 to 10 meters/sec. Still further according to this definition, the defined extraction environment includes inert gases and/or condensable vapor phases in the range of pressures from 1 to 10000 kPa.
Another general object of the present invention is to provide new, improved therapeutic formulations and compositions of CFSE which can be used for dermatological treatment of a number of skin and mucosal membrane conditions in humans and animals. These conditions include but are not limited to: skin dryness/allergies/rashes, tissue healing, prevention of scaring complications, fungal infections, treatment of minor burns, etc.
The invention includes various physical forms of the CFSE formulations (emulsions, liposomes, aerosols) which are not available commercially or reported in the scientific literature. It is believed that the bioavailability of CFSE is enhanced in fine-dispersed forms relative to typical bulk-solution forms.
The invention includes therapeutic and dermatological formulations in various physical forms with high concentration levels of CFSE e.g., higher than any known "comfrey" preparations or published "comfrey" treatment protocols. Liquid preparations according to this invention contain CFSE components in excess of 0.02 wt. % of the total weight of the final preparation as used. The use of such enriched formulations according to this invention, thus allows smaller quantities of the preparation to be used to deliver the same amount of active components of the Symphytum extract.
For emulsion-type formulations, this invention includes topical CFSE consisting of O/W emulsions, oil being the dispersed phase and water the continuous phase, for the purpose of protecting, moisturizing, and stimulating the healing processes of skin or mucous membrane.
Skin-treatment O/W emulsion formulations according to this invention contain selected oils for moisturizing the skin, especially the stratum corneum and high levels of CFSE in the water phase for maximal healing properties.
This invention also includes improved methods for use of CFSE formulations in alternative physical forms including liquid emulsions such as foam, spray, gel, lotion, cream, ointment, and dispersed vesicles, particles or droplets solid- or liquid-aerosols, liposomes, microemulsions, for maximum effectiveness in wound healing.
This invention includes new methods for controlled-release of CFSE impregnated into a fibrous matrix or blended with an adhesive.
Patients with AIDS usually experience skin breakdown problems, e.g., folliculitis, "itchy red bumps", psoriasis, and dry itchy skin. Topical emulsion preparations of CFSE according to this invention significantly relieve the itching in many cases and help promote healthier skin.
Healthcare workers--because of frequent hand washing and wearing surgical gloves--often experience dermatitis, i.e., severe chapping and dryness of the skin. Topical emulsion-type CFSE formulations according to this invention reduce dryness and, in many cases, stimulate healing to point that the skin becomes healthy again. Similarly, workers who are exposed to irritating substances in their occupation can use similar CFSE/formulations for either therapeutic or prophylactic purposes.
Diabetic patients often experience dry skin and in some cases stasis ulcers which heal with difficulty. Topical emulsion-type CFSE formulations according to this invention help relieve the dryness and in some cases has proven to be a good healing agent for the stasis ulcers.
Paraplegics or bedridden patients can experience pressure sores or decubitus ulcers. Topical emulsion-type CFSE formulations according to this invention help condition the skin and thus prevent the formation of the ulcers. Further, the formulations will stimulate the healing of those ulcers already extant.
Other uses for emulsion-type CFSE formulations according to this invention include: diaper rash, chapped or dry skin, sunburn, insect bites, minor wounds, cold sores, athlete's foot, and minor burns.
A secondary objective of this invention is the preparation and use of therapeutic compositions containing CF Taxus Extracts (CFTE) for treatment various forms of malignant disorders, cell-proliferative diseases and carcinomas. Specific extraction processing parameters fall in the ranges noted above for CFSE. This invention also includes improved methods for use of CFTE formulations in alternative physical forms including liquid emulsions, foam, spray, gel, lotion, cream, ointment, and dispersed vesicles, particles or droplets solid- or liquid-aerosols, liposomes, microemulsions, for maximum effectiveness in treatment of carcinomas, cell-proliferative diseases and malignant disorders. This invention includes new methods for controlled-release of CFTE impregnated into a porous/fibrous matrix or blended with an adhesive.
A tertiary objective of this invention is the preparation and use of therapeutic compositions containing CF Aloe Extracts (CFAE) for skin injuries/burns, inflammations, infections, and diseases. Specific extraction processing parameters fall in the ranges noted above for CFSE. This invention also includes improved methods for use of CFAE formulations in alternative physical forms including liquid emulsions, foam, spray, gel, lotion, cream, ointment, and dispersed vesicles, particles or droplets solid- or liquid-aerosols, liposomes, microemulsions, for maximum effectiveness in treatment of skin diseases, injuries, inflammations, and allergies/sensitizations. This invention includes new methods for controlled-release of CFAE impregnated into a porous/fibrous matrix or blended with an adhesive.
One preferred formulation of this invention is an O/W emulsion with at least 0.02 wt. % of active components within CFSE prepared as described in the following.
CF Symphytum Extract preparation. Preferably, fresh Symphytum leaves/stems or roots are used, and at least 12 grams of roots or 60 grams of leaves/stems are comminuted into one liter of liquid aqueous extracting fluid. Alternatively CF Symphytum Extract is made by comminuting at least 6 grams of dried Symphytum leaves and stems or dried roots and combining it with one liter of liquid aqueous extracting fluid. In this context, "dried" denotes less than 10 wt. % water, on an absolute or "bone-dry" basis. The forced-convection-contact-velocity differential for the process should be in the range 0.01 to 10 meter/sec.
For another preferred embodiment, the extracting fluid may be an undiluted or "neat" liquid such as propylene glycol, glycerol, ethyl alcohol, water, methylene chloride and the chamber environment is the vapor of the liquid at a pressure of about 100 kPa. Alternatively, the extract fluid may be a liquid solution or two-phase emulsion. The extraction process requires approximately 72 hours contact at temperatures between 20 and 30 deg. C. The forced-convection-contact-velocity differential for the process should be in the range 0.01 to 10 meter/sec. The supernatant extract is filtered thru typical food-type paper filters (nominal pore size 10-100 micrometers).
In the case of extraction with a physiologically-compatible solution (generally isotonic to blood and tissue, 250-350 mOsm/kg), the filtrate may be used directly to prepare final liquid formulations for use in intravenous, subcutaneous, intramuscular, intralymphatic, intraperitoneal, or intraplueral preparations.
Alternatively, the filtrate may be evaporated to reduce the extractant to as little as zero %. To facilitate preparation of certain formulations or physical forms, the extraction step can be done with water or aqueous solutions containing a reduced level of physiologic components (such as saline) and the final adjustment to physiologic osmolality range being accomplished by addition of specific concentrates to the filtered CF Symphytum Extract.
The concentrated filtrate can be added directly to the water phase or it can be re-suspended with an alternative vehicle, e.g. water, glycerol, propylene glycol. One kilogram of the final formulation contains CF Symphytum Extract from at least 6 grams of dried leaves and stems or roots, or the extract from at least 60 grams of fresh leaves/stems or the extract from at least 12 grams of fresh roots.
In typical O/W emulsions, the volume percent of the dispersed phase is in the range of 0.1-25 vol. %. For these formulations, the major quantity of CF Symphytum Extract is contained in the water-solution phase of the emulsion, whether it is a simple O/W emulsion or a complex W/O/W emulsion wherein water is the continuous phase and the primary dispersed phase is oil droplets which in turn contain smaller droplets of the continuous phase, water. W/O/W dispersions may also be called double or multiple emulsions.
Liposome dispersions of CFSE can be made spontaneously by the technique of adding a quantity of aqueous extract solution to a dry film of lipid or phospholipid. Other known alternative methods of forming liposomes such as injection, reverse-micelle formation and reverse-phase evaporation can also be used to produce liposomes from aqueous CFSE. The therapeutic characteristics of the resulting vesicles can be tailored for specific diseases or tissue applications by: (a) altering the average diameter/size of the vesicle, (b) altering the surface charge of the vesicle, (c) altering the stiffness of the encapsulating vesicle membrane-film and (d) incorporation of antibodies or ligands into the vesicle surface/film which show binding or affinity for specific types/forms of tissue.
Aerosol dispersions of solid- or liquid-phase CFSE can be made by techniques such as atomization, nebulization, spray drying, freeze drying.
CFTE Extraction Technics
fluid type: water, C1-C10 alcohols, C1-C3 ketones, C1-C4 acetates, C1-C4 ethers, C1-C3 halocarbons, and solutions/dispersions thereof in liquid and/or vapor phases
pressure range: 0.1X<vapor pressure of most-volatile fluid component at maximum extraction temperature in cycle, deg. C.<20X
temperature range: 15-110 deg. C.
mass-transport parameters: 0.01/1<weight ratio input plant parts/extract<10000/1 0.01<forced-convection-contact-velocity differential, meter/sec<10 total diffusional contact time: 1<cycle time, hours<200
CFTE Formulations and Use Technics
A wide variety of CFTE formulations can be made; these include topical, transdermal, transmucosal, parenteral compositions in fluid-forms i.e., solutions, suspensions, emulsions, and fine-disperse forms such as foams, liposomes, vesicles, micelles and aerosols. Known pharmaceutical excipients appropriate to the specific administration mode and use-form can be blended with CFTE. For therapy of carcinomas and malignant disorders, parenteral forms of CFTE can be used; however, targeted liposome formulations adapted for breast or uterine tumor treatment are preferred.
CFAE Extraction Technics
fluid type: water, C1-C10 alcohols, C1-C3 ketones, C1-C4 acetates, C1-C4 ethers, C1-C3 halocarbons, and solutions/dispersions thereof in liquid and/or vapor phases
pressure range: 0.1X<vapor pressure of most-volatile fluid component at maximum extraction temperature in cycle, kPa at max. temp deg. C.<20X
temperature range: 15-110 deg. C.
mass-transport parameters: 0.01/1<weight ratio input plant parts/extract<10000/1 0.01<forced-convection-contact-velocity differential, meter/sec<10 total diffusional contact time: 1<cycle time, hours<200
CFAE Therapeutic Formulations and Use Technics
A wide variety of CFAE formulations can be made; these include topical, transdermal, transmucosal, parenteral compositions in fluid-forms i.e., solutions, suspensions, emulsions, and fine-disperse forms such as foams, liposomes, vesicles, micelles and aerosols. Known pharmaceutical excipients appropriate to the specific administration mode and use-form can be blended with CFAE.
Group A. Examples of processes for: (a) preparation of the Symphytum plant materials to be extracted and (b) the preparation including refining (filtration/concentration/purification) of CFSE.
Example A1. Peri-Harvest Treatment Protocol 1012
This is a process of peri-harvest conditioning/treatment/handling of the plant materials i.e., leaves, stems and/or roots, of Symphytum species which preserves their medicinal agents against evaporation, chemical degradation and photochemical interactions in the time interval between harvest and initiation of the extraction contact including the steps of:
(a) by visual inspection and other chemical/microbiological tests, selecting zones of the production field which contain Symphytum plants which have reached an optimum level of maturity (peri-bloom stage) and areessentially free of disease and have no significant levels of undesirable materials/bacteria (e.g., pyrrolozidine alkaloids) or adventitious contaminants,
(b) treating selected zones of plants to be harvested with solutions containing for example viable Lactobacillus planterum which can reduce thenumbers of undesirable adventitious bacteria such as E. coli or Klebsiella,
(c) charging the harvested plant materials immediately (within a time period of 10-50 minutes) into a closed collection apparatus which preventsexposure to sunlight, and
(d) transferring the collected plant materials into specialized extraction apparatus for additional processing.
Example A2. Compression/Liquid-Fluid Extraction Process for Concentrating Symphytum Extracts
This is a method of compacting/comminuting/extracting fresh plant materialsof Symphytum species which includes the steps:
(a) receiving collected plant materials from an enclosed in-field collection/processing apparatus (see Example A1 above),
(b) comminuting the plant materials to small pieces (avg. length or thickness dimension approx. 1 mm) by known processes such as chopping or macerating,
(c) charging the comminuted plant material into a closed reactor adapted toprovide controlled ranges of internal pressure, temperature and forced-convection-contact-velocity differential within a time interval of 2-6 hours after receipt,
(d) charging the reactor with a liquid or liquid-mixture extracting fluid such as alcohol or water or propylene glycol or glycerol or mixtures of these components at a selected temperature in the range between 15-55 deg.C.,
(e) contacting the enclosed plant materials under sealed environmental conditions for a time of 2 to 100 hours, preferably 4-8 at a pressure of 50-200 kPa, with controlled mechanical agitation by means of blades, or a rotating/tumbling reactor chamber, and
(f) treating the extract mixture (fluid and solids) by one or more mechanical separation methods such as sedimentation, centrifugation, filtration, etc., to separate the solid matter. Additional diatomaceous-earth filtration treatment of pre-treated liquid from prior steps may be used to remove color bodies.
Example A3. Preservation Technics For CFSE
For the case of liquid-fluid aqueous extract solutions (from Example A2 above) which must be stored for extended periods in a bulk tank (to prevent growth of microbes) by either:
(a) adding a small amount (0.001 to 1.0 wt. %) of one or more chemical preservatives such as methyl and propyl paraben, or blends thereof, or
(b) dewatering the active CFSE to a dry-powder form by vacuum evaporation, spray drying, freeze drying,
Example A4. Air Drying and Storage-Preparation Process for Symphytum Plant Elements
This is a process for preparing harvested Symphytum plant elements to be stored for extraction at a future time which includes the steps of:
(a) removing water from the plant elements to reduce their water content to10 wt. % or less, by a flow of heated, dried air (50% RH max, max. air temperature below 65 deg. C., times may range from 10 to 100 hours depending upon the actual RH and flow rate) through a loose bed or across the surface, starting at step (d) of Example A1. above, and
(b) charging the resulting dried plant elements into sealed, radiation-impervious containers along with an inert, air-excluding fluid atmosphere such as volatile alcohol or fluorocarbon which prevents chemical degradation of the active constituents.
Group B. Examples of different topical O/W-emulsion dermatologic formulations which contain CFSE, e.g., ointment, salve, lotion, cream, spray, infusion fluids, etc. In these examples, the CF Symphytum Extract is dissolved into the indicated quantity of carrier solution or base such as water, glycerol, propylene glycol.
Example B1. Water-Based CF Symphytum Extract Solution
______________________________________A. Water Phase CFSE 2-20 grams distilled water 1000 grams methyl paraben 1 gram propyl paraben 0.5 gram______________________________________
Example B2. DH100 formulation
______________________________________ % by weight______________________________________A. Water Phase methyl paraben 17.0 grams 0.102% propyl paraben 8.5 grams 0.051% triethanolamine 903. grams 5.433% allantoin 152. grams 0.914% deionized or distilled 9375. grams 56.402% water CF Symphytum ext. in 2340. grams 14.078% glycerolB. Oil Phase stearic acid 600. grams 3.611% glyceryl monostearate 1575. grams 9.476% cetyl alcohol 840. grams 5.054% olive oils 320. grams 1.925% castor oil 230. grams 1.384% jojoba oil 230. grams 1.384% myrrh oil 30. grams 0.180% peppermint oil 1.25 grams 0.008% 16,621.75 gramsC. Heat both phases to 73° C. pour A into B while mixing to form a W/O/W emulsion. Continue mixing until the temperature of the mixture is 65° C. or less.______________________________________
Example B3. SCP100 formulation
______________________________________ % by weight______________________________________A. Water Phase CF Symphytum Ext. in 624. grams 13.675% glycerol, or deionized or 3.250. grams 71.225% distilled water allantoin 50. grams 1.096% methyl paraben 5. grams .111% propyl paraben 2.5 grams .055% diazolidinyl urea 10.5 grams .230%B. Oil Phase stearic acid 144. grams 3.156% cetyl 208. grams 4.558% olive oil 54. grams 1.183% castor oil 34. grams .745% jojoba oil 34. grams .745% myrrh oil 10. grams .219% polyoxyethylene (2) 34. grams .745% stearyl ether polyoxyethylene 21 103. grams 2.257% stearyl ether 4,653. grams______________________________________C. Heat both phases to 73° C. Pour A into B while mixing to form a W/O/W emulsion. Continue mixing until the temperature of the mixture is 50° C. or less.______________________________________
Example B4. DC102 formulation
______________________________________ % by weight______________________________________A. Water Phase methyl paraben 1. grams .100% propyl paraben 0.2 grams .020% CF Symphytum Ext. in 150. grams 14.851% glycerol allantoin 10. grams .990% sodium ascorbate 10. grams .990% polysorbate 80 10. grams .990% deionized water 576. grams 57.030%B. Oil Phase stearic acid 40. grams 3.960% glyceryl monostearate 105. grams 10.396% steryl alcohol 56. grams 5.544% liquid petrolatum 52. grams 5.149% 1,010. gramsC. Heat both phases to 73° C. While mixing add B into A to form a W/O/W emulsion. Continue mixing until the temperature of the mixture is 50° C. or less.______________________________________
Example B5. DC139 formulation
______________________________________ % by weight______________________________________A. Water Phase methyl paraben 20. grams .100% propyl paraben 4. grams .020% CF Symphytum Ext. in 2953. grams 14.794% propylene glycol allantoin 204. grams 1.022% polysorbate 80 200. grams 1.002% deionized or distilled 11,520. grams 57.713% waterB. Oil Phase stearic acid 800. grams 4.008% glyceryl monostearate 2100. grams 10.521% stearyl alcohol 1120. grams 5.611% liquid petrolatum 1040. grams 5.210% 19,961. gramsC. Heat both phases to 73° C. Pour B into A while mixing to form an O/W emulsion. Continue mixing until the temperature of the mixture is 50° C. or less.______________________________________
Example B6. SCP293 formulation
______________________________________ % by weight______________________________________A. Water Phase methyl paraben 20. grams .097% propyl paraben 12. grams .058% CF Symphytum Ext. in 3084. grams 14.980% glycerol allantoin 202. grams .980% triethanolamine 400. grams 1.900% distilled water 15,000. grams 72.880%B. Oil Phase stearic acid 268. grams 1.300% glyceryl monostearate 700. grams 3.400% cetyl alcohol 374. grams 1.820% olive oil 214. grams 1.040% castor oil 168. grams .820% jojoba oil 100. grams .490% myrrh oil 40. grams .190% peppermint oil 1.25 grams .006%C. Heat both phases to 73° deg. C. Pour A into B while agitating to form a water-in-O/W emulsion. Continue mixing until the temperature of the mixture drops below 50° C.______________________________________
From 0.5-5.0 wt. % of Melaleuca uncinata oil (frequently called Tea Tree oil) can be added to any of the examples (B1 to B6 above) for the purpose of inhibition of fungal growth at a dermal application site e.g., athlete's foot treatment, applied between toes.
Group C. Examples of non-emulsion CF Symphytum Extract pharmaceutical formulations i.e., single-phase solutions, vesicles, liposome, micelles, aerosols, tablets, microcapsules, caplets, injectable fluids, transdermal delivery patch/device, etc.
Example C1. Isotonic Liposome Formulation LS141
Isotonic liposomes are desirable for application of CFSE to sensitive tissue, wounds, mucous membrane, or as an ingredient in an injectable, implantable, or inhalable preparation.
Use water phase from example B1 above; adjust the solution osmolality to physiologic range (250-350 mOsm/kg) by the addition of concentrates containing physiologic salts, glucose, etc.. Form the liposome by adding the solution to a dry film of lipid such as lecithin or cholesterol; use sonication if needed.
Example C2. Aerosol Formulations A293
Aerosol formulations are of particular value in application of CFSE to hairy areas of human or animal bodies. In order to prepare lyophilized solid forms of CF Symphytum Extract, the extraction stage would be done with a minimal amount of water or alcohol to facilitate dewatering by evaporation, spray drying or freeze drying. Solid aerosols can be used with pressurized propellants in devices which meter and disperse the dry particles into a gas-type aerosol which may be inhaled for treatment of nasal membranes.
For liquid dispersions, a known vesicle- or emulsion-stabilizing agent is dissolved into a volatile, biocompatible propellant-solvent such as R-12 fluorocarbon. The resulting fluid is packaged into a pressurized propellant spray device to facilitate direct external application to scalp, skin or mucosal tissue.
Example C3. Transdermal/Transmucosal formulation A291
CFSE such as Example B1 above are blended with known skin adhesive compounds to produce a diffusion-controlled drug delivery reservoir. Additional selected therapeutic agents may also be added for specific functions such as: (a) low levels of DMSO for enhancing the rate of absorption of the Symphytum healing agents into the skin, or (b) or synergistically increasing the healing properties of the CFSE e.g., D-alphatocopherol in transmucosal adhesive devices.
Example C4. Microencapsulated formulations M 17-19
Dry-powder forms of CFSE such as Example B1 dewatered by the process of Example A3(b), are encapsulated as microspheres (0.01 to 1.0 mm diam.) within thin, polymeric membranes using known spray-drying technics. These forms can be used for controlled release in transdermal, transmucosal, enteral, or parenteral preparations.
D. Examples of selected methods of using various formulations of CFSE (see Groups A., B. and C. above).
Example D1. Adhesive patch for delivering controlled amounts/rates (skin, mucous membrane). Aqueous emulsion CFSE is added during the preparation ofa known hydrogel adhesive for use on human skin so that the resulting cast layer or film serves as a reservoir matrix and a diffusion-controlled delivery means for the active agents of the extract.
Example D2. Conductive electrode adhesive formulations with CF Symphytum Extract (TENS, long-term EKG monitoring, iontophoresis, etc.).
One frequent complication of transdermal electrostimulation for the relief of pain is a skin rash which develops in the tissue layers subject to the effects of the material, current pulses and the conductive electrode gels/creams. Similarly, electrocardiac monitoring apparatus, such as a Holter monitor, and iontophoresis devices also can produce painful skin rashes. CFSE are blended into the conductive paste or the skin adhesive toalleviate these conditions (see Example D1 above).
Example D3. Impregnated tampon for delivering selected CF Symphytum Extractdosage to intravaginal membranes. An emulsion formulation such as Example B2 with Tea-Tree oil addition is used. Alternatively, a liposomal formulation such as Example C1 is used; by the addition of a binding ligand or antibody specific for the critical fungal vector e.g., candida albicans, to the vesicle surface, the vesicles is targeted directly towardthe infectious process.
Example D4. Microencapsulated or dry-powder aerosol forms of CFSE such as Example C2. is administered by known metering aerosol devices for the treatment of throat or nasal irritations/inflamations which may occur in accident situations involving poison-gas attacks, fires, explosions, and exposures to irritating chemical vapors/mists.
Example D5. Liquid aerosol or liposome forms of CFSE is administered by a spray dispenser for scalp treatment e.g., sunburn or hair-loss. For enhanced hair-growth stimulation, CFSE are blended into known compounds. Similarly, for the treatment of aging and skin wrinkles, CFSE are blended with compounds which are known to improve the elastic tone and thickness of the skin layer structure; for such conditions, a known acoustic or ultrasonic device is used along with the application to accelerate absorption into the skin.
Example D6. Wax-type suppository for colitis treat. CFSE are blended into aknown suppository vehicle prior to forming the suppository device.
Example D7. CFSE for Treating Skin Conditions Related to HIV Virus Study 2303--10 patients, formulation of Example B2 used for about 6 months for eczema, folliculitis, and dry itchy skin.
RESULTS: About half the patients indicated symptomatic relief and requestedadditional supplies of the formulation for continuing use.
Example D8. CFSE for Treating Skin Lesions Related to Kaposi's Sarcoma (KS)in HIV Population Study 1011--Small-group test of formulation of Example B2. Used for KS skin wounds/eruptions.
RESULTS: Formulation cleared up most skin problems and closed spots.
Example D9. CFSE for Skin Problems In Diabetes Population Study 805. Group of 98 diabetes patients used formulation in Example B6 over a period of about 30 days for treatment of dry skin and other diabetes-related skin complications. Written evaluation instrument given to each participant to mail in at the completion of the test period. For the preliminary report, the data on 39 questionnaire responses was analyzed.
RESULTS: About 87% of the respondents indicated that the formulation was satisfactory or very satisfactory for the relief of dry-skin complications.
EXAMPLE E. Therapeutic Validation of CFTE in Mammals
Known in-vivo testing methods can be used to evaluate the cytotoxic and cell-proliferation-inhibition effectiveness of CFTE, e.g., subcutaneous injections, murine animal model, daily dose range 0.01 to 1 ml/kg of active agents based upon total body weight or the specific organ weight. In-vitro testing methods for CFTE include inhibition of murine monocyte activation. It is believed that the cytocidal mechanism is similar to thatof other alkaloids, i.e., inhibition of the formation of microtubules in tumor cells.
On the basis of confirmation by such lab tests and animal studies, it is expected that CFTE formulations are useful in treating mammalian adenocarcinomas and tumors of specific organs such as the kidney, liver, pancreas, breast, colon, prostate and esophagus. Various sterile-fluid formulations/vehicles/excipients may be used for parenteral administrationof CFTE, including single-phase solutions, emulsions, suspensions, foams, or liposomes. Using known methods for controlled release or volume blending, CFTE formulations can be added to IV solutions. It is believed that CFTE formulations also potentiate or enhance the mammalian immune response through various interactions including inhibition of protein kinase C.
EXAMPLE F. Therapeutic Validation of CFAE in Mammals
On the basis of confirming lab tests and animal studies, it is expected that CFAE formulations are useful in many topical compositions for treating skin dryness, irritation, bums, abrasions sensitization to skin electrodes and other conditions. CFAE may be used with significant benefitalong with CFSE in many of the topical formulations.
EXAMPLE G. Additional Therapeutic Formulations of CFSE, CFTE, and CFAE For Mammals.
CFSE, CFTE, and CFAE medicaments described above may be further modified bythe addition of one or more of the following general types of agents: antibiotics, analgesics, enzymes (such as elastase, collagenase, lipase), steroids (such as hydrocortisone), vitamins (such as A, B, C, E), hormones, biotin cofactors, emollients (such as lanolin), immunoglobulins,vaccines and other immumologic agents.
The preceeding examples of this invention can be repeated with similar success by substituting the generically or specifically described reagentsfor those used in the examples.
From the examples presented and previous descriptions, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various startingmaterials, body-healing usages and administration forms/conditions.
|Patente citada||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US4670263 *||15 Nov 1985||2 Jun 1987||Noorlander Daniel O||Nontoxic, germicide, and healing compositions|
|1||*||Chemotaxonomy pp. 545 549 ibid.|
|2||Chemotaxonomy pp. 545-549 ibid.|
|3||*||Phytoalexins pp. 519 521, vol. 13, McGraw Hill Encyclopedia of Science and Technology, 7th Ed., 1992.|
|4||Phytoalexins pp. 519-521, vol. 13, McGraw Hill Encyclopedia of Science and Technology, 7th Ed., 1992.|
|Patente citante||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US5531988 *||28 Oct 1994||2 Jul 1996||Metagenics, Inc.||Bacteria and immunoglobulin-containing composition for human gastrointestinal health|
|US5549830 *||28 Feb 1994||27 Ago 1996||Napro Biotherapeutics, Inc.||Reverse osmosis and ultrafiltration methods for solutions to isolate desired solutes including taxane|
|US5683712 *||14 Sep 1995||4 Nov 1997||Avantgarde S.P.A.||Transdermal patch for the administration of homeopathic drugs|
|US6180099||17 Abr 1998||30 Ene 2001||Metagenics, Inc.||Method of using immunoglobulin and fiber-containing compositions for human health|
|US6241983||26 May 1999||5 Jun 2001||Metagenics, Inc.||Bacteria-and fiber-containing composition for human gastrointestinal health|
|US6387255||9 Feb 1998||14 May 2002||Bayer Aktiengesellschaft||Triphase extraction column|
|US6495579||1 Jun 1998||17 Dic 2002||Angiotech Pharmaceuticals, Inc.||Method for treating multiple sclerosis|
|US6506387 *||20 Abr 1999||14 Ene 2003||Paxa N.V.||Method for preparing aloin by extraction|
|US6506411||19 Abr 1999||14 Ene 2003||Angiotech Pharmaceuticals, Inc.||Anti-angiogenic compositions and methods of use|
|US6515016||1 Dic 1997||4 Feb 2003||Angiotech Pharmaceuticals, Inc.||Composition and methods of paclitaxel for treating psoriasis|
|US6524628||6 Nov 2000||25 Feb 2003||Idaho Research Foundation, Inc.||Pressurized water extraction|
|US6670523 *||20 Dic 1999||30 Dic 2003||Ivf Hartmann Ag||Tampon with infection-protection|
|US6689803||5 Feb 2002||10 Feb 2004||Angiotech Pharmaceuticals, Inc.||Compositions and methods for treating surgical adhesions|
|US7066884||16 Mar 2001||27 Jun 2006||Sontra Medical, Inc.||System, method, and device for non-invasive body fluid sampling and analysis|
|US7432069||5 Dic 2005||7 Oct 2008||Sontra Medical Corporation||Biocompatible chemically crosslinked hydrogels for glucose sensing|
|US8224414||13 Sep 2005||17 Jul 2012||Echo Therapeutics, Inc.||System and method for analyte sampling and analysis with hydrogel|
|US8287483||5 Mar 2004||16 Oct 2012||Echo Therapeutics, Inc.||Method and apparatus for enhancement of transdermal transport|
|US8313760||22 Abr 2008||20 Nov 2012||Angiotech International Ag||Compositions and methods for coating medical implants|
|US8372420||3 Sep 2009||12 Feb 2013||Angiotech International Ag||Compositions and methods for coating medical implants|
|US8386027||25 Abr 2008||26 Feb 2013||Echo Therapeutics, Inc.||Skin permeation device for analyte sensing or transdermal drug delivery|
|US8425927||4 Nov 2010||23 Abr 2013||Angiotech International Ag||Compositions and methods for coating medical implants|
|US8812071||6 Mar 2008||19 Ago 2014||Echo Therapeutics, Inc.||Transdermal analyte monitoring systems and methods for analyte detection|
|US8870810||13 Sep 2012||28 Oct 2014||Echo Therapeutics, Inc.||Method and apparatus for enhancement of transdermal transport|
|US20030100846 *||16 Mar 2001||29 May 2003||Linda Custer||System, method, and device for non-invasive body fluid sampling and analysis|
|US20040043052 *||27 May 2003||4 Mar 2004||Angiotech Pharmaceuticals, Inc.||Compositions and methods for coating medical implants|
|US20040091541 *||16 Jul 2003||13 May 2004||Unger Evan C.||Solid matrix therapeutic compositions|
|US20040171980 *||5 Mar 2004||2 Sep 2004||Sontra Medical, Inc.||Method and apparatus for enhancement of transdermal transport|
|US20040236268 *||5 Mar 2004||25 Nov 2004||Sontra Medical, Inc.||Method and apparatus for enhancement of transdermal transport|
|US20050079229 *||24 Jul 2003||14 Abr 2005||Cawthon Garret D.||Methods, compositions and systems for the prevention and treatment of diaper rash|
|US20050182450 *||7 Dic 2004||18 Ago 2005||Angiotech International Ag||Electrical devices and anti-scarring agents|
|US20050182467 *||7 Dic 2004||18 Ago 2005||Angiotech International Ag||Electrical devices and anti-scarring agents|
|US20050182468 *||7 Dic 2004||18 Ago 2005||Angiotech International Ag||Electrical devices and anti-scarring agents|
|US20050187600 *||26 Nov 2004||25 Ago 2005||Angiotech International Ag||Electrical devices and anti-scarring agents|
|US20050192647 *||7 Dic 2004||1 Sep 2005||Angiotech International Ag||Electrical devices and anti-scarring agents|
|US20060015058 *||25 Feb 2005||19 Ene 2006||Kellogg Scott C||Agents and methods for enhancement of transdermal transport|
|US20060094944 *||13 Sep 2005||4 May 2006||Sontra Medical Corporation||System and method for analyte sampling and analysis with error correction|
|US20060094946 *||13 Sep 2005||4 May 2006||Sontra Medical Corporation||System and method for analyte sampling and analysis with hydrogel|
|US20060141074 *||8 Feb 2006||29 Jun 2006||Kimberly-Clark Worldwide, Inc.||Composition for neutralizing house dust mite feces|
|US20060282123 *||7 Dic 2004||14 Dic 2006||Angiotech International Ag||Electrical devices and anti-scarring agents|
|US20070128681 *||5 Dic 2005||7 Jun 2007||Sontra Medical Corporation||Biocompatible chemically crosslinked hydrogels for glucose sensing|
|US20070270447 *||31 Jul 2007||22 Nov 2007||Angiotech International Ag||Compositions and methods for coating medical implants|
|US20080089952 *||31 Jul 2007||17 Abr 2008||Angiotech International Ag||Compositions and methods for coating medical implants|
|US20080113035 *||10 Ago 2007||15 May 2008||Angiotech International Ag||Compositions and methods for treating or preventing inflammatory diseases|
|US20080145514 *||31 Jul 2007||19 Jun 2008||Angiotech International Ag||Compositions and methods for coating medical implants|
|US20080153900 *||10 Ago 2007||26 Jun 2008||Angiotech International Ag||Compositions and methods for treating or preventing imflammatory diseases|
|US20080191103 *||10 Feb 2006||14 Ago 2008||Lorne Thurgar||Clip|
|US20080281178 *||6 Mar 2008||13 Nov 2008||Echo Therapeutics, Inc.||Transdermal analyte monitoring systems and methods for analyte detection|
|US20100268288 *||10 Feb 2010||21 Oct 2010||Angiotech International Ag||Electrical devices and anti-scarring agents|
|EP1582210A2||2 Dic 1997||5 Oct 2005||Angiotech International AG||Compositions and methods for treating or preventing surgical adhesions|
|EP2075014A2||27 May 2003||1 Jul 2009||Angiotech International Ag||Compositions and methods for coating medical implants|
|WO2007096924A2 *||14 Feb 2007||30 Ago 2007||Maiello Adolfo||Extraction, preparation and use of active principles of the aloe plant for producing self-meditaion devices such as controlled-release gauzes, bandages, stockings, elastic bands and arch supports|
|Clasificación de EE.UU.||424/405, 514/965, 514/937, 424/450, 424/47, 424/45, 424/43, 424/DIG.15, 424/401, 424/725, 424/44, 436/829|
|Clasificación internacional||A61Q19/00, A61K8/97, A61K9/127, A61Q17/00, A61K8/14, A61K36/00, A61L26/00, A61Q7/00, A61K36/63, A61K36/185, A61K36/30, A61K36/534, A61K36/47, A61K36/328|
|Clasificación cooperativa||Y10S424/15, Y10S514/937, Y10S436/829, Y10S514/965, A61K36/534, A61K36/30, A61K36/63, A61L2300/30, A61L26/0066, A61Q19/00, A61K36/47, A61K36/328, A61L2300/404, A61K36/185, A61L2300/626, A61Q19/007, A61K8/97, A61L26/0057, A61Q17/00, A61K9/127, A61K8/14, A61Q7/00|
|Clasificación europea||A61K36/185, A61K36/328, A61K36/30, A61K36/534, A61K36/63, A61K36/47, A61K8/14, A61L26/00H2, A61L26/00F, A61Q19/00, A61K9/127, A61K8/97|
|2 Jul 1998||FPAY||Fee payment|
Year of fee payment: 4
|2 Jul 1998||SULP||Surcharge for late payment|
|13 Feb 2002||REMI||Maintenance fee reminder mailed|
|19 Jul 2002||LAPS||Lapse for failure to pay maintenance fees|
|17 Sep 2002||FP||Expired due to failure to pay maintenance fee|
Effective date: 20020719